RxDoctor Payments Data

Jean-Francois Eid, MD

Urology · New York, NYNPI 1174630032

Payments from drug & device makers

$145,562in general payments, 2019–2025

Across 209 payments — averaging $696.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$127K
  • Boston Scientific$15K
  • Rigicon,inc.$2K
  • Endo Pharmaceuticals Inc.$458
  • Kowa Pharmaceuticals America, Inc.$210
  • Urovant Sciences Inc$101
  • plus $133 from 4 others

What the payments were for

  • Consulting fees$26,46118%
  • Speaking & faculty fees$72,96550%
  • Travel & lodging$5,9834%
  • Food & beverage$4,0893%
  • Education$36,06525%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast123$127,073
Boston Scientific38$15,468
Rigicon,inc.4$2,120
Endo Pharmaceuticals Inc.26$458
Kowa Pharmaceuticals America, Inc.7$210
Urovant Sciences Inc4$101
Astellas Pharma US Inc3$56
AbbVie2$32
180 Medical, Inc.1$23
Dentsply IH Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,562 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$244,228
Medicare patients
324
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron42$28,718
GemtesaVibegron11$12,239
Tadalafil85$7,554
Tamsulosin Hcl160$3,957
Cephalexin90$1,898
Finasteride58$1,122
Alfuzosin Hcl ErAlfuzosin Hcl45$934
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen79$867
Solifenacin Succinate18$653
Dutasteride11$375
Fluconazole13$317
Ibuprofen77$304
Acetaminophen-CodeineAcetaminophen With Codeine32$271
Ciprofloxacin Hcl15$122
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$56$28,71842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →